A 62-year-old woman with splenic marginal zone lymphoma presented with fever, cough and bilateral pneumonia 11 days after chemotherapy. A bronchoalveolar lavage showed numerous leukocytes and Gramnegative bacilli that were identified as Bordetella bronchiseptica in culture. An antibiotherapy with minocycline and ciprofloxacin helped her to stop coughing. This unusual micro-organism, which has mainly an animal reservoir, is a rarely cause of human infection, almost always in immunocompromised patients. The main problems in B. bronchiseptica infection are the difficulties of identification of this micro-organism and the recurrence of infection, which are a challenge for microbiologists and practitionners.
INTRODUCTION
Bordetella bronchiseptica is a Gram-negative coccobacillus that commonly causes respiratory tract infections in many mammalian species [1, 2] . Human infection with Bordetella bronchiseptica is a rare condition that actually occurs almost always in immunocompromised patients, mainly in HIV infected patients [2] [3] [4] . The difficulties of identification of this bacterium and the recurrence are the main problems of B. bronchiseptica infection [5] . We report herein a case of B. bronchoseptica bilateral lung infection in a woman with splenic marginal zone lymphoma.
CASE REPORT
A 62-year-old woman was admitted to our hospital for recurrence of splenic marginal zone lymphoma. Her past medical history included diabetes mellitus, splenectomy and hypothyroidism. HIV serology was negative. She did not have a history of chronic respiratory disease (asthma, emphysema, or chronic bronchitis) or of exposure to tobacco smoke. She lived on a farm in Algeria 20 years ago but returned occasionally from France to Algeria and had significant exposure to cats, dogs and to rabbits. However, at the time of admission she earned no pet. She had severe lymphoma recurrence with liver and bone marrow infiltration and received a single R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine, and prednisone) infusion through a central catheter that was taken off after chemotherapy administration. At day 11 after chemotherapy, she presented with cough and fever. Physical examination revealed no hypotension, normal respiratory frequency but diminished oxygen saturation of 86% (arterial haemoglobin) on room air, no abdominal pain, no diarrhoea. Chest examination found bilateral crepitant rales and normal heart auscultation. Laboratory values showed 840/mm 3 white blood cells with 15/mm 3 neutrophils and 790/mm 3 lymphocytes, haemoglobin 8.3 g/dl, platelets 28,000/mm 3 , normal hepatic tests; C-reactive protein 256 mg/l, serum creatinin 59 µmol/l. Urinary legionella antigen and serum aspergillus antigen were negative. Chest X-ray and Computed Tomography scan showed bilateral pneumonia. Treatment for severe pneumonia was started with cefepim 4 g/day and amikacin 1 g/day. Direct examination of bronchoalveolar lavage showed numerous leukocytes and Gram-negative bacilli. The sample was inoculated onto anaerobic blood agar, chocolate agar in an atmosphere of 5% carbon dioxyde, Drigalski agar at ambiant atmosphere, and incubated at 37˚C. Multiple small, convex, spheroidal colonies approximately 1 mm in diameter were isolated after 24 h (10 5 bacteria/ml of bronchialveolar lavage). The isolate was catalase-and oxidase-positive, motile and peritrichous, and strictly aerobic. It was also positive in tests for urease, nitrate reduction and citrate utilization, and negative for indole, hydrolysis of esculin and gelatin, and acid production from carbohydrates, including D-glucose, D-mannitol, D-maltose, L-arabinose, D-mannose and D-saccharose. The organism was identified as Bordetella bronchiseptica by using the API 20NE systems (bioMérieux, Marcy l'Etoile, France); this identification was confirmed by 16S rRNA sequencing (100% of nucleotide identity with the sequence of B. bronchiseptica RB50, GenBank accession No. NC002927) over a 518 bp DNA fragment amplified and sequenced with primers 5'-AGAGTTTGATCC-TGGYTCAG-3' and 5'-CTTTACGCCCARTAAWTC-CG-3' and analyzed in the GenBank database: www. ncbi.nlm.nih.gov/genbank. Identification was confirmed by the French National Reference Centre for Bordetellosis. Serologies (IgG anti-pertussis toxin) before infection and one month after the onset of clinical symptoms were negative. Cefepim and amikacin were changed for ticarcillin-clavulanic acid 12,000 mg/day and ciprofloxacin 800 mg/day for 5 days with a good efficacy on fever. Cough was still present. Ticarcillin-clavulanic acid was stopped and replaced by minocycline 200 mg/day. The patient received a treatment with tetracycline and ciprofloxacin for a total of 21 days which helped to stop coughing. She died two weeks after antibiotics discontinuation of lymphoma induced severe lactic acidosis. Bordetella bronchiseptica commonly causes respiretory tract infections in many mammalian species, including cats, dogs and laboratory animals [1, 2] . Bordetella bronchiseptica is a rarely reported cause of human infection, mainly respiratory infections, although atypical clinical presentations have been reported (like meningitis, endocarditis, peritonitis) [3, 8, 9] . The respiratory illnesses ranged in severity from mild upper respiratory tract infection to cavitary pneumonia and bacteraemia or shock and could lead to death. B. bronchiseptica is considered as an opportunistic infection associated with immunocompromised patients, mainly in HIV infected patients but also malignant haematological underlying disease (leukaemia, Hodgkin's disease, and multiple myeloma), transplant patients or various immunodeficiencies (alcohol addiction, cystic fibrosis…) [3, 10, 11] . Infections have also been described in immunocompetent persons but always in a specific context such as post-surgery, trauma, hemodialysis, or respiratory infections [9, 10] . Often, however not necessary, a contact with an appropriate animal reservoir is reported [3] [4] [5] 11] .
DISCUSSION
The occurrence of Bordetella bronchiseptica infection results on the patient's underlying immunosuppression and the ability of Bordetella bronchiseptica to inhibit leukocyte function and to adhere to respiratory epithelial cells [12] . The abilities of B. bronchiseptica to colonize and to establish upper respiratory tract infection depend on the production of virulence factors. Bordetella bronchiseptica synthesizes all of the factors implicated in B. pertussis virulence (adhesins, such as filamentous hemagglutinin, fimbriae, and pertactin and toxins such as dermonecrotic toxin, tracheal cytotoxin, type III secretion system, endotoxin and adenylate cyclase-hemolysin) except for pertussis toxin [5, 10, 13, 14] .
The optimal therapy for B. bronchiseptica infections has not been clearly established, but the response to a number of antimicrobial agents appears to be similar to that expected for nonfermentative Gram-negative bacilli. However, despite the good in vitro activities of these antibiotics, the clinical responses to them have often been disappointing. The in vitro susceptibility tests using a disk diffusion technique on Mueller-Hinton agar according to the Antibiogram Committee of the French Microbiology Society showed that this bacterium was susceptible to aminoglycosides (amikacin, tobramycin and gentamicin, but not streptomycin), ticarcillin, piperacillin, ceftazidime and imipenem, fluoroquinolones (although MIC of ciprofloxacin appear near the susceptibility breakpoint), tetracyclins, trimethoprim-sulfamethoxazole and chloramphenicol. It was resistant to cefoxitin, cefamandole, cefotaxime, aztreonam. The aminoand carboxy-penicillins alone appear to be less effective than their association with beta-lacatamase inhibitor, it might be explained of the beta-lactamase BOR-1 in B. bronchiseptica, a naturally occuring penicillinase [15] . The principal problem in B. bronchiseptica infection is the recurrence, needing a long duration of treatment.
CONCLUSION
Our report underscores that unusual micro-organisms from nonhuman sources are potential serious pathogens in patients who are immunocompromised. The difficulties of identification of these micro-organisms, which can induce a therapeutic delay, are a challenge for practitioners.
